Nang Kuang Pharmaceutical Co., Ltd. (TPE:1752)

Nang Kuang Pharmaceutical Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	309.49	301.54	378.48	401.2	417.12	266.46
Trading Asset Securities	-	-	-	1.31	1.28	1.39
Cash & Short-Term Investments	309.49	301.54	378.48	402.51	418.41	267.85
Cash Growth	26.50%	-20.33%	-5.97%	-3.80%	56.21%	-31.93%
Accounts Receivable	415.48	423.08	374.67	386.71	350.44	373.82
Other Receivables	0.23	0.12	1.3	0.15	0.4	1.95
Receivables	415.7	423.2	375.97	386.86	350.84	375.77
Inventory	720.45	709.06	762.62	827.58	701.44	768.39
Prepaid Expenses	21.99	20.36	20.61	23.38	20.71	23.1
Other Current Assets	4.57	1.83	-	-	-	-
Total Current Assets	1,472	1,456	1,538	1,640	1,491	1,435
Property, Plant & Equipment	2,111	2,105	1,867	1,602	1,682	1,702
Long-Term Investments	109.12	129.12	152.18	118.97	50.29	60.2
Other Intangible Assets	3.98	4.34	5.2	3.87	5.21	3.45
Long-Term Deferred Tax Assets	25.24	22.02	39.36	27.07	29.84	22.91
Other Long-Term Assets	90.2	95.99	255.08	192.61	169.83	36.72
Total Assets	3,811	3,813	3,856	3,585	3,429	3,260
Accounts Payable	201.49	210.38	166.8	254.3	224.34	188.21
Accrued Expenses	107.81	113.99	100.61	-	-	-
Short-Term Debt	400	450	580	370	479.99	380
Current Portion of Long-Term Debt	15.11	19.86	12.5	12.5	12.5	52
Current Portion of Leases	0.75	0.75	0.49	1.05	1.26	0.45
Current Income Taxes Payable	38.86	11.78	2.7	57.01	46.61	16.77
Current Unearned Revenue	113.56	123.9	127.97	142.49	131.55	121.38
Other Current Liabilities	278.1	212.17	291.63	203.04	176.7	191.22
Total Current Liabilities	1,156	1,143	1,283	1,040	1,073	950.03
Long-Term Debt	190.87	167.26	112.5	25	37.5	50
Long-Term Leases	-	0.37	0.07	0.59	1.55	0.43
Long-Term Deferred Tax Liabilities	-	0.35	-	1.2	0.26	0.39
Other Long-Term Liabilities	30.1	30.1	30.1	53.33	23.06	0.1
Total Liabilities	1,427	1,391	1,479	1,174	1,189	1,056
Common Stock	1,010	1,010	1,010	1,010	1,010	1,010
Additional Paid-In Capital	245.01	325.8	426.79	457.09	482.34	492.43
Retained Earnings	1,129	1,086	940.46	944.03	748.02	702.24
Comprehensive Income & Other	-0.04	-0.04	-0.03	0.02	-0.04	-0.03
Shareholders' Equity	2,384	2,422	2,377	2,411	2,240	2,205
Total Liabilities & Equity	3,811	3,813	3,856	3,585	3,429	3,260
Total Debt	606.73	638.23	705.56	409.13	532.81	482.88
Net Cash (Debt)	-297.24	-336.69	-327.08	-6.62	-114.4	-215.03
Net Cash Per Share	-2.93	-3.33	-3.23	-0.07	-1.13	-2.12
Filing Date Shares Outstanding	100.99	100.99	100.99	100.99	100.99	100.99
Total Common Shares Outstanding	100.99	100.99	100.99	100.99	100.99	100.99
Working Capital	316.52	313.17	254.99	599.94	418.44	485.09
Book Value Per Share	23.61	23.98	23.54	23.87	22.18	21.83
Tangible Book Value	2,380	2,418	2,372	2,407	2,235	2,201
Tangible Book Value Per Share	23.57	23.94	23.49	23.84	22.13	21.80
Land	767.41	767.41	573.57	247.28	247.28	247.28
Buildings	1,232	1,232	1,134	1,120	1,111	1,105
Machinery	2,614	2,586	2,506	2,431	2,359	2,224
Construction In Progress	121.78	56.54	26.79	36.53	41.57	33.93

Source: S&P Global Market Intelligence. Standard template. Financial Sources.